26.05.2024, 706 Zeichen

Valneva: Valneva, a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (CSO) and Executive Committee member, effective June 3, 2024. Dr. Schuitemaker brings more than two decades of experience in vaccine discovery and development. She formerly served as Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson (J&J), with responsibility for the strategy and execution of vaccine programs on COVID-19, HIV, RSV, Ebola, and multiple other viral disease targets for almost 14 years.
Valneva: weekly performance: -5.37%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (20/05/2024)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1196 feat. Opening Bell-Miterfinderin Karin Bauer: ATX etwas fester, mehr Streubesitz bei der Porr, 35 Jahre Agrana-IPO

Bildnachweis

Aktien auf dem Radar:Porr, Kapsch TrafficCom, AT&S, Semperit, RHI Magnesita, Amag, OMV, Lenzing, Strabag, Addiko Bank, FACC, Flughafen Wien, Frequentis, Gurktaler AG VZ, Heid AG, Reploid Group AG, Marinomed Biotech, Bajaj Mobility AG, voestalpine, BKS Bank Stamm, Austriacard Holdings AG, EuroTeleSites AG, CPI Europe AG, Österreichische Post, Telekom Austria, UBM, Fresenius Medical Care, Rheinmetall, SAP, Volkswagen Vz., BMW.

---